19 and older, any sex, with Cervical Cancer or Uterine Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Hospital StayPrimary· 1 Month
Length of hospital stay for patients undergoing laparotomy on the gynecologic oncology service measured as whole days from the day of surgery until discharge
Group
Value
95% CI
Control Group (Standard Laparotomy)
3.0
2.0 – 3.0
Rapid Recovery Group
3.0
2.0 – 3.0
Pain Medications UsedSecondary· Post operative - day 2
Total daily narcotic pain medication used by patients. Narcotic use was standardized by conversion to morphine equivalents using the methods of Korff et al.
Group
Value
95% CI
Control Group (Standard Laparotomy)
10.0
8.3 – 12.3
Rapid Recovery Group
7.5
3.3 – 10.0
Pain AssessmentSecondary· Day 0
Secondary outcome is to determine if rapid recovery can improve Visual Analogue Scale (VAS) for pain assessment. VAS scales are a horizontal line 100 mm in length with the left end labeled 'No pain' and the right end labeled 'Very severe pain'. The subject marks a point on the line that represents their perception of their current state. VAS score is determined by measuring the distance (mm) from the left end of the line to the point on the line marked by the subject. The range of possible values for this pain score is 0 to 100 mm.
Group
Value
95% CI
Control Group (Standard Laparotomy)
4.33
3.0 – 6.25
Rapid Recovery Group
3.13
2.30 – 4.40
Adverse events — posted to ClinicalTrials.gov
Time frame: 1 year.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Over 600,000 hysterectomies are performed annually in the United States. Despite increasing use of less invasive approaches, the majority of hysterectomies are still performed via traditional laparotomy, which can be associated with generally slower recovery and longer lengths of post-operative hospitalization. Rapid Recovery Protocols (RRP) seek to optimize post-surgical morbidity outcomes by returning a patient to normal physiology as quickly as possible following surgery.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07094165 — The Effects of Dexmedetomidine and Remifentanil on Kidney Injury After Muscle Compression Injury in Rats
· NA
· completed
NCT04985695 — Influence of Analgesic Technique on Post Operative Rehabilitation After Median Laparotomy
· NA
· recruiting
NCT04791735 — Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma
· NA
· active not recruiting
NCT04575935 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
· Phase 3
· recruiting
NCT04258631 — Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients Wit
· Phase 4
· completed
Other recruiting trials for Cervical Cancer
Currently open trials in the same condition.
NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
· Phase 2
· recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
· Phase 1
· recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)
· NA
· recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
· NA
· recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
· Phase 2
· recruiting
Other Masonic Cancer Center, University of Minnesota trials
Trials by the same sponsor.
NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies
· NA
· not yet recruiting
NCT06584929 — Rural Smoking Cessation
· NA
· not yet recruiting
NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect
· NA
· recruiting
NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
· Phase 2
· recruiting
NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
Last refreshed: 17 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01705288.